Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Takahashi, T. [1 ]
Mori, K. [1 ]
Mizuno, R. [1 ]
Mamesaya, N. [1 ]
Kobayashi, H. [1 ]
Omori, S. [1 ]
Wakuda, K. [1 ]
Ono, A. [1 ]
Naito, T. [1 ]
Murakami, H. [1 ]
Kenmotsu, H. [1 ]
机构：
[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.235
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1651P
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [21] A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC).
    Socinski, MA
    Weissman, CH
    Hart, LL
    Beck, JT
    Choksi, JK
    Hanson, JP
    Prager, D
    Bloss, LP
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 661S - 661S
  • [22] Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice
    Sebastian, M.
    Barlesi, F.
    Califano, R.
    Mansfield, A. S.
    Blackhall, F. H.
    Flahavan, E. M.
    Davies, J.
    Arnold, P.
    Morris, S.
    Reck, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] COST OF IMMUNOTHERAPY TO TREAT EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
    Bilir, S. P.
    Ogale, S.
    VALUE IN HEALTH, 2020, 23 : S36 - S36
  • [24] A phase II study of biweekly irinotecan plus cisplatin in patients with extensive stage small cell lung cancer
    Bae, S.
    Kim, M.
    Shin, S.
    Lee, K.
    Hyun, M.
    Song, H.
    Kwon, K.
    Park, K.
    Lee, W.
    EJC SUPPLEMENTS, 2005, 3 (02): : 338 - 338
  • [25] A phase II study of biweekly irinotecan plus cisplatin in patients with extensive stage small cell lung cancer
    Lee, Won Silk
    Bae, Sung Hwa
    ANNALS OF ONCOLOGY, 2007, 18 : 183 - 184
  • [26] Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)
    Paz-Ares, L.
    Juan-Vidal, O.
    Carcereny, E.
    Greillier, L.
    Navarro, A.
    Bennouna, J.
    Santoro, A.
    Berardi, R.
    Besse, B.
    Salvagni, S.
    Gonzalez, H.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    Ponce, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S482 - S483
  • [27] Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)
    Paz-Ares, L.
    Johnson, M. L.
    Girard, N.
    Hann, C. L.
    Ahn, M-J.
    Nishio, M.
    Godard, J.
    Laadem, A.
    Yoshizuka, N.
    Qian, M.
    Cheng, B.
    Rudin, C. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1255 - S1256
  • [28] NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC).
    Ellis, Peter Michael
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Goss, Glenwood D.
    Olivo, Martin Sebastian
    Powers, Jean
    Walsh, Wendy
    Seymour, Lesley
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive-stage small-cell lung cancer (WJTOG 0301)
    Iwamoto, Y.
    Kobayashi, M.
    Matsui, K.
    Yamamoto, H.
    Yamazaki, K.
    Saka, H.
    Sawa, T.
    Shibata, K.
    Takeda, K.
    Nakagawa, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] PHASE II STUDY OF IRINOTECAN PLUS CISPLATIN FOLLOWED BY AMRUBICIN IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (WJTOG 0301)
    Iwamoto, Y.
    Kobayashi, M.
    Matsui, K.
    Yamamoto, H.
    Yamazaki, K.
    Saka, H.
    Sawa, T.
    Shibata, K.
    Takeda, K.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 117 - 117
12345